115th Congress (2017–2019) · House bill · Sponsor: Rep. Walden, Greg [R-OR-2]
This page covers HR2430 in the 115th Congress. Bill numbers start over every Congress, so HR2430 in another Congress is a different bill.
| Item | Detail |
|---|---|
| Roll-call votes | 2 |
| Chamber | Senate |
| Latest vote | 2017-08-03: Bill Passed (94-1) |
| Latest action | 2017-08-18: Became Public Law No: 115-52. |
| Policy area | Health |
| Official record | Congress.gov |
(This measure has not been amended since it was passed by the House on July 12, 2017. The summary of that version is repeated here.) FDA Reauthorization Act of 2017 TITLE I–FEES RELATING TO DRUGS Prescription Drug User Fee Amendments of 2017 (Sec. 102) This bill amends the Federal Food, Drug, and Cosmetic Act to extend through FY2022 and revise Food and Drug Administration (FDA) user fees for brand name drugs. User fees are eliminated for supplemental new drug applications and drug manufacturing facilities. A prescription drug program fee replaces the prescription drug product fee. This annual fee is assessed on a new drug application holder for each approved drug for up to five drugs. The total user fee revenue amount is adjusted annually for changes in review process capacity needs, to provide for operational reserves, and for additional direct costs. Eighty percent of revenues must be generated by prescription drug program fees, with the remainder from application fees. (Sec. 103) The bill extends through FY2022 requirements for annual reports and consultation by the FDA on reauthorization of brand name drug user fees. TITLE II–FEES RELATING TO DEVICES Medical Device User Fee Amendments of 2017 (Sec. 203) The bill extends through FY2022 and revises FDA user fees for medical devices. A user fee is established for requests to classify devices that are not substantially equivalent to marketed devices. The FDA’s authority to waive or reduce device user fees in the interest of public health is eliminated. (Sec. 204) The bill extends through FY2022 requirements for…
Subjects: Administrative law and regulatory procedures, Cancer, Child health, Congressional oversight, Department of Health and Human Services, Drug safety, medical device, and laboratory regulation, Drug therapy, Executive agency funding and structure, Food and Drug Administration (FDA), Fraud offenses and financial crimes
Every recorded vote on this bill, newest first, with a link to the official tally. Member-by-member positions are on each member’s profile.
| Date | Chamber | Question | Result | Yea | Nay | Not voting | Record |
|---|---|---|---|---|---|---|---|
| 2017-08-03 | Senate | On Passage of the Bill H. R. 2430 | Bill Passed (94-1) | 62 | 1 | 1 | Official tally |
| 2017-08-03 | Senate | On Cloture on the Motion to Proceed H. R. 2430 | Cloture on the Motion to Proceed Agreed to (96-1, 3/5 majority required) | 63 | 1 | 0 | Official tally |
HR2430 (FDA Reauthorization Act of 2017) was introduced in the 115th Congress (2017–2019) by Rep. Walden, Greg [R-OR-2].
On 2017-08-18: Became Public Law No: 115-52.
2 recorded votes in the 115th Congress. The most recent, on 2017-08-03, was "On Passage of the Bill H.R. 2430": Bill Passed (94-1).